News Releases

Date Title and Summary View
Apr 13, 2001
Johnson & Johnson Conference Call on First-Quarter Earnings
Johnson & Johnson Conference Call on First-Quarter Earnings NEW BRUNSWICK, N.J., April 13 -- Johnson & Johnson will host a conference call for financial analysts at 8:30 a.m. on Tuesday, April 17, 2001. Robert J. Darretta, Vice President, Finance, Chief Financial Officer and member of the Executive
Mar 27, 2001
Johnson & Johnson to Merge With ALZA Corporation In $10.5 Billion Stock-for-Stock Transaction
Johnson & Johnson to Merge With ALZA Corporation In $10.5 Billion Stock-for-Stock Transaction NEW BRUNSWICK, N.J. and MOUNTAIN VIEW, Calif., March 27 -- Johnson & Johnson (NYSE: JNJ - news), the world's most comprehensive and broadly based manufacturer of health care products, and ALZA Corporation
Mar 26, 2001
REMINDER/NYC Police and Fire Commissioners, NYSE Chairman and Johnson & Johnson - Merck to Join Forces to Honor the NYSE Fallen Heroes Fund
Donate $25,000 Check to New York Stock Exchange Fallen Heroes Fund
Mar 02, 2001
Johnson & Johnson Acquires BabyCenter From eToys, Inc. Leading Online Destination for Parents Plans for Continued Expansion of Operations
Johnson & Johnson Acquires BabyCenter From eToys, Inc. Leading Online Destination for Parents Plans for Continued Expansion of Operations NEW BRUNSWICK, N.J., March 2 -- Johnson & Johnson (NYSE: JNJ) has acquired BabyCenter, Inc., from eToys, Inc. (Nasdaq: ETYS).
Mar 02, 2001
Correction - Johnson & Johnson
Correction - Johnson & Johnson In NYF033, Johnson & Johnson (NYSE: JNJ ) Acquires BabyCenter From eToys, Inc. (Nasdaq: ETYS), moved earlier today, we are advised by a representative of the company that the contact phone number for Ken Ross should read "310-998-6993" rather than "301-998-6993" and
Feb 28, 2001
ADVISORY/Reminyl, New Treatment for Alzheimer's Disease, Receives FDA Approval
ADVISORY/Reminyl, New Treatment for Alzheimer's Disease, Receives FDA Approval -- Reminyl® (galantamine hydrobromide) -- a new treatment for mild to moderate Alzheimer's disease derived from the bulbs of daffodils -- was approved Feb. 28 by the U.S. Food and Drug Administration (FDA).
Feb 13, 2001
Johnson & Johnson Board Elects James T. Lenehan and William C. Weldon Vice Chairmen of the Board
Johnson & Johnson Board Elects James T. Lenehan and William C. Weldon Vice Chairmen of the Board NEW BRUNSWICK, N.J., Feb. 13 -- The Johnson & Johnson Board of Directors yesterday elected two of the Company's executives, James T. Lenehan and William C.
Feb 08, 2001
Cordis Coronary Stent Receives Broader Indication
Cordis Coronary Stent Receives Broader Indication MIAMI, Feb. 8 -- Cordis Corporation, the Johnson & Johnson company that pioneered the first coronary artery stent for elective use, today reported U.S. Food and Drug Administration (FDA) approval to market its Bx VELOCITY™ coronary artery stent
Feb 05, 2001
FDA Grants Conditional 'IDE' Approval to Cordis for Pivotal Clinical Study Of Sirolimus-Coated Bx VELOCITY(TM) Stents
FDA Grants Conditional 'IDE' Approval to Cordis for Pivotal Clinical Study Of Sirolimus-Coated Bx VELOCITY(TM) Stents WARREN, N.J., Feb. 5 -- Cordis Corporation today reported it received permission from the U.S. Food and Drug Administration (FDA) to commence a randomized pivotal clinical study in
Feb 02, 2001
Johnson & Johnson to Participate in the Merrill Lynch Global Pharmaceuticals, Biotechnology & Medical Devices Conference '2001: A Healthcare Odyssey'
Johnson & Johnson to Participate in the Merrill Lynch Global Pharmaceuticals, Biotechnology & Medical Devices Conference '2001: A Healthcare Odyssey' NEW BRUNSWICK, N.J., Feb. 2 -- Johnson & Johnson will participate in the Merrill Lynch Global Pharmaceuticals, Biotechnology & Medical Devices
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.